After a drug fails in clinical trials, there is a tendency to retail every related detail permanently. There are strategies to optimize the storage and organization of legacy information, paper as well as electronic, about a specific drug, rather than maintaining this information in diverse repositories and locations.
Information in a jumbled state is very expensive way to manage and maintain vital information and is often lost or very difficult to locate. Converting all legacy paper records to an electronic format and organizing them can be daunting.
The total costs associated with submissions to regulatory agencies are astronomical. Some of these expenses are not easily eliminated. Labor costs are almost always the major expense in any organization. Project man-hours can be significantly reduced by better controls for the storage, retrieval and conversion of essential information. Of course another financial return is gained by the acceleration of the submission process.
This session by expert speaker Dr. Charlie Sodano will analyze the implications of big data and the storage, retail and conversion of information on drug manufacturers.
Who should attend?
Ask a question at the Q&A session following the live event and get advice unique to your situation, directly from our expert speaker.
- Dr. Jerry Lanese,
- Jennifer Diaz,
- Norma Skolnik,
- Dr. David Lim, Ph.D., RAC, ASQ-CQA
- Paul Lorcheim, P.E.
- Ginette Collazo, Ph.D.
Charlie Sodano began his career as a discovery research chemist at Pfizer, and since1985 has specialized in the management of electronic and paper information and records.
He holds BS and MS and Ph.D. degrees in Chemistry and has more than 30 years’ experience in the design, improvement and roll-out of electronic records and information management and archiving systems. He managed Information Services departments at...
More Events By The Speaker